SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Kairos Pharma, LTD.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% beneficial ownership stake in Kairos Pharma, LTD., holding 1,696,924 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
• The Reporting Persons beneficially own an aggregate of 1,696,924 shares of Kairos Pharma, LTD.'s Common Stock, par value $0.001 per share.
• This ownership represents 9.99% of the total class of Kairos Pharma, LTD. common stock.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Kairos Pharma, LTD.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client, which is the direct holder of the reported shares. Steven Boyd is the managing member of Armistice Capital, LLC.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.

Key Dates

Keywords

Kairos Pharma, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, SEC filing, investment management, institutional investor, equity stake